UTI Vaccine

Recurrent UTIs can be effectively treated with a simple UTI vaccine where other methods of mainstream management are no longer working.


Recently the use of vaccine / immunostimulation in patients with recurrent infections has become more popular.  The science behind this won a Nobel Prize for medicine in 2010 and has been very popular on the continent although very few trials have been performed to date.

At Reading the first randomised controlled trial in the use of vaccines for urinary tract infections is currently underway.  It is a two-year trial so we await those results.

The vaccine has been used in a number of patients on a named-patient basis and a recent publication in the British Journal of Urology (please click on the box below to follow a link to the publication).

This research data suggests a 70-80% reduction in infections in a one-year period for patients who have tried all other treatments, and is looking very promising.

Patients often rely on repeated and prolonged courses of antibiotics, in particular in prostatitis where current international guidelines recommend 2-4 weeks of antibiotic treatment.  However with the alarming rise of antibiotic resistance worldwide, descried as one of the biggest risks to global health in our lifetime, and with the World Health Organisation triggering a Global Action Plan to combat antibiotic resistance, there is a pressing need to find viable alternatives.

The Urology Partnership are proud to have presented and published nationally and internationally on the first experience in the United Kingdom of the UTI vaccine Uromune® in preliminary cohorts of both men and women with recurrent UTIs that have failed mainstream managements including antibiotic prophylaxis.

The UTI vaccine is a sublingual immunomodulator, currently pre-licence in the phase III development stage.

Our conclusions from preliminary results of these patients suggest that the vaccine is both effective and safe in UK men and women with recurrent UTIs, suggesting it may offer a potentially viable alternative to antibiotic prophylaxis.  We have recently had a paper accepted in the British Journal of Urology International (BJUI)  following our successful study, please click this link for the scientific PubMed reference.

This is a new exciting treatment and we are very happy to discuss any questions you may have regarding the UTI vaccine, just give us a call or send us an email on info@theforburyclinic.co.uk.

Success of Uromune® and number of further infections following vaccination with Uromune® treatment.
Success of Uromune® and number of further infections following vaccination with Uromune® treatment. Reference: BJU Int. 2017 Nov 23. First experience in the UK of treating women with recurrent urinary tract infections with the bacterial vaccine Uromune®. Yang B1, Foley S1,2.

Get fast access to leading specialists for the swift diagnosis and treatment of urological conditions in a private clinic environment.

If you would like more information or wish to arrange a consultation with one of our specialist consultant urological surgeons then please either Call 0118 920 7040 or complete the form below.

Insured patients

Contact your GP and ask for a referral to the Urology Partnership.

All consultations, investigations and treatments are covered by major insurance companies (depending on policy).

Funding your own treatment

Self-funding initial consultation fee is £205. Follow up fees are £165.

Consultation charges are exclusive of any tests and other investigations that the consultant may wish to carry out.

If you are making an appointment on behalf of someone else, please complete the form with their details but add your own name and contact details into the "further information" box.

* Denotes a required field

We may contact you by email, SMS or phone about your enquiry. If we try to contact you by phone (mobile and/or landline) and you are not available, we may leave you a voicemail message. We may also use your details to contact you about patient surveys we use for improving our service or monitoring outcomes, which are not a form of marketing.